Herbas VPB

Print
EN | LT
LT - SYNERGISTIC EFFECTS BETWEEN AURISTATIN-BASED ANTIBODY DRUG CONJUGATES AND INHIBITORS OF THE PI3K-AKT MTOR PATHWAY
EN - SYNERGISTIC EFFECTS BETWEEN AURISTATIN-BASED ANTIBODY DRUG CONJUGATES AND INHIBITORS OF THE PI3K-AKT MTOR PATHWAY

Legal status

Patent not validated

Bibliographic data
Indications of the International Patent Classification (IPC)
(51) INT.CL. A61K 47/68
A61K 45/06
A61K 31/46
A61K 31/4375
A61P 35/00
European patent
(11) Number of the document 2629801
(13) Kind of document T
(96) European patent application number 11835158.4
Date of filing the European patent application 2011-10-20
(97) Date of publication of the European application 2013-08-28
(45) Date of publication and mention of the grant of the patent 2019-05-15
(46) Date of publication of the claims translation
PCT application
(86) Number PCT/US2011/057130
Date 2011-10-20
PCT application publication
(87) Number WO 2012/054748
Date 2012-04-26
Priority applications
(30) Number Date Country code
201161445785 P 2011-02-23 US
405767 P 2010-10-22 US
Inventors
(72)
LEWIS, Timothy S., US
LAW, Che-Leung, US
MCEARCHERN, Julie A., US
Grantee
(73) Seattle Genetics, Inc., 21823 30th Drive, S.E., Bothell, WA 98021, US
Title
(54) SYNERGISTIC EFFECTS BETWEEN AURISTATIN-BASED ANTIBODY DRUG CONJUGATES AND INHIBITORS OF THE PI3K-AKT MTOR PATHWAY
  SYNERGISTIC EFFECTS BETWEEN AURISTATIN-BASED ANTIBODY DRUG CONJUGATES AND INHIBITORS OF THE PI3K-AKT MTOR PATHWAY
Last update date 2021-04-30